Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 11/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19334154 | 0.96 | PRCP (0.51) | PRCPKCNH2CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL19334068 | 0.94 | PRCP (0.49) | PRCPKCNH2CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL19578092 | 0.92 | PRCP (0.52) | PRCPKCNH2CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL19334250 | 0.91 | PRCP (0.51) | PRCPKCNH2CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL19334230 | 0.90 | PRCP (0.49) | PRCPKCNH2CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL26321363 | 0.89 | PRCP (0.52) | PRCPKCNH2CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL19334162 | 0.86 | PRCP (0.50) | PRCPKCNH2CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL19578405 | 0.86 | PRCP (0.44) | PRCPKCNH2CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL19334175 | 0.86 | PRCP (0.54) | PRCPKCNH2CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL19334075 | 0.85 | KCNH2 (0.59) | PRCPKCNH2CYP3A4CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | PRCP 190/4885KCNH2 4523/4885CYP3A4 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.